Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Pfizer taps Blackstone for $1.5B to pave path to GLP-1 launch
Pfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund development of its monthly GLP-1 receptor agonist.
Nick Paul Taylor
Nov 12, 2026 4:15am
Fierce Pharma
AZ’s reported $10B offer for Rhythm fuels talks of a bidding war
Nov 5, 2026 9:36am
Pfizer trims obesity pipeline, axes phase 2 lung disease asset
Nov 3, 2026 8:02am
Verdiva axes GLP-1 switching trial over ‘market evolution’
Oct 14, 2026 10:13am
Biomea posts data to pitch oral GLP-1 to potential partners
Oct 14, 2026 9:23am
Zealand inks $1.2B Generate pact for anti-obesity protein R&D
Oct 14, 2026 4:08am